Overall, with respect to the dosage schemes of the different drugs, the most effective drug to reduce the viability of T-PLL cancer cells was venetoclax (BCL2 inhibitor inducing apoptosis), which was tested for both analyzed T-PLL cohorts. Here, BCL2 is linked to cancer.